Several reports indicate that early osteolytic activity is needed for prostate cancer (PCa) bone metastases to become established but eventually PCa switches to an osteoblastic phenotype through unknown mechanisms. Wnts promote skeletal formation, osteoblast differentiation and bone remodeling. Accordingly, we explored if altered Wnt signaling in the bone microenvironment impacts the bone metastatic phenotype. We found that PCa cells express Wnt and Wnt inhibitor DKK-1 and that Wnts contribute to PCa's ability to nduce osteoblastic activity. Furthermore, DKK-1 inhibited PCa-osteoblastic activity and DKK-1 decreases in PCa bone metastases. Accordingly, we hypothesize that DKK-1 acts as a molecular swith that transitions PCacells from osteolytic (high DKK-1 expression and Wnt inhibition) to osteoblastic (low DKK-1 expression and permissive for Wnt) activity as the PCa progresses in the bone. To test this, we will perform the following Aims.
Aim 1. Define the role of temporal downregulation of DKK-1 in PCa bone metastases. We will perform in vivo murine studies using an inducible promter driving DKK-1 cDNA or anti-DKK-1 antibody to temporally increase or decrease DKK-1 activity, respectively, in early and late stages of PCa bone metastases. We will then evaluate effects on tumor establishment and progression in bone and the bone phenotype.
Aim 2. Determine the mechanism(s) through which DKK-1 impacts PCa-induced bone remodeling. We will determine (1) how modulation of DKK-1 in PCa cells affects their ability to induce osteoblast differentiation and (2) how DKK-1, in the context of PCa, alters osteoblasts ability to interact with other bone remodeling pathways including BMPs, VEGF, ET-1 and RANKL. This will be done through a series of in vitro experiments using osteoblast cell lines and primary osteoblasts.
Aim 3. Identify mechanisms that regulate DKK-1 expression in bone metastatic PCa cells. We have found that parathyroid hormone-related protein (PTHrP) decreases DKK-1 expression. We will extend these studies to determine the ability of PHTrP to regulate DKK-1 expression at the protein, mRNA and promoter levels and determine the mechanism through which PTHrP regulates DKK-1 promoter activity in PCa and determine how this impacts the PCa bone metastatic phenotype in vivo. When completed, this proposal will have elucidated if temporal regulation of DKK-1 expression accounts for the ability of PCa skeletal metastases to transition from an osteolytic to an osteoblastic phenotype and the mechanisms through which DKK-1 is switched off and how that modulates bone remodeling in PCa bone metastases.

Public Health Relevance

Spread of prostate cancer (PCa) to bone is a common and painful complication of PCa. Understanding the mechanisms of how PCa interacts in the bone will help identify therapies to inhibit this frequent complication of PCa.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176

Showing the most recent 10 out of 228 publications